Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
MindMaze Therapeutics Holding SA develops and commercializes precision digital treatments for neurological diseases and brain disorders. Its brain technology platform integrates software, proprietary sensors, telehealth, and AI-driven data analytics to support care from acute hospital treatment to outpatient and home-based therapy.
Company news covers FDA-cleared and CE-marked neurotherapeutics for areas such as stroke and Parkinson's disease, reimbursement strategy across healthcare systems, clinical validation, and R&D expansion into adjacent neurological indications. Updates also include the completed business combination that formed the MindMaze Therapeutics identity, along with shareholder voting, governance, capital-structure, and financial-reporting matters.
Relief Therapeutics announced the appointment of Gilles Della Corte, M.D. as Chief Medical Officer, effective immediately. Della Corte brings over 40 years of experience in the biopharmaceutical industry, enhancing Relief's leadership as it advances its lead compound, aviptadil, in clinical trials aimed at treating severe COVID-19. The company has also engaged Virtuoso Sarl to manage clinical trials in Europe, while U.S. trials will be managed by NeuroRx. Aviptadil has shown promise in clinical settings and has received Fast Track Designation from the FDA.
Relief Therapeutics successfully up-listed from OTC Pink to OTCQB on August 31, 2020, enhancing its visibility to a broader investor base. This milestone signifies compliance with stringent reporting and verification requirements. Alongside, the company raised funds through a Share Subscription Facility, increasing total shares to approximately 2.53 billion. Relief holds around CHF 32 million in cash, intended for clinical trials of its lead candidate Aviptadil for COVID-19 related conditions. The company aims to target a regulated exchange like NASDAQ in the future.